Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reissue Patent
1999-06-16
2002-03-19
Ketter, James (Department: 1636)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007100, C435S344100, C435S329000, C435S325000, C530S388100, C530S388150, C530S388200, C530S388850, C530S387500
Reissue Patent
active
RE037596
ABSTRACT:
The invention relates to monoclonal antibodies (MAbs) and fragments thereof which bind to defined tumor-associated antigens, principally of small cell lung carcinoma (SCLC), of melanoma, of neuroblastoma and other tumors of neuroectodermal origin, to hybridoma cells for the preparation thereof, and to the antigens which can be defined and/or isolated with the aid of these antibodies or antibody fragments. The antibodies, antibody fragments and antigens can be used as diagnostic aid, active substance or active substance carrier.
The identification, characterization and therapy of tumors is one of the most important areas of diagnosis and therapy. Development in this area has made great advances owing to the possibility of producing monoclonal antibodies of high specificity. Particularly important in this connection has proven to be the identification of so-called tumor markers. By tumor markers are meant products of the tumor cell, for example tumor-associated antigens, but also substances formed by the healthy tissue as reaction of the body to the malignant growth. Examples of known tumor markers are CEA, AFP but also tumor antigens defined by monoclonal antibodies, such as, for example, CA 19-9 or CA 125.
The main area of use of tumor markers in in vitro diagnosis is in the therapy and monitoring the progress of tumor patients. Certain tumor markers can also be employed for differential diagnosis or for screening of risk groups.
A number of tests have already been carried out for the identification of small cell lung carcinoma (SCLC). Thus, for example, it is known that there is increased formation of neuron-specific enolase, an isoenzyme of enolase (EC 4.2.1.11), by malignant tumors of neuroectodermal origin, such as, for example, small cell bronchial carcinoma or neuroblastoma, and increased serum concentrations thereof occur in tumor patients.
However, it has emerged that false negative results are given by some of the patients suffering from the above-mentioned tumors. Furthermore, since red blood cells, but also platelets, contain relatively large amounts of NSE, it is the case that, owing to lysis thereof, falsely raised NSE serum or plasma levels and thus false positive values are measured (Pahlman et al., Tumor Biology 5: 127-139, 1984).
European Patent Application 0,323,802 discloses a monoclonal antibody against a cell surface antigen of lung carcinomas. However, MAIER et al. (Br. J. Cancer, 1989, 59, 692-695) disclose that the antibody SWA 20 used in EP 0,323,802 recognizes an epitope (cluster 5) which showed a moderately to strongly positive reaction only with 45% of tested SCLC samples.
It is therefore desirable to produce another specific tumor marker, which is independent of NSE, for neuroblastoma and small cell lung carcinoma.
REFERENCES:
patent: 4503143 (1985-03-01), Gerber et al.
patent: 5284931 (1994-02-01), Springer et al.
patent: WO-0323802 (1989-07-01), None
Schol et al., “MAb 123C3 identifying SCLC phenotype in lung tumors, recognizes mainly, but not exclusively, endocrine and neuron-supporting normal tissues,” Int. J. Cancer 2(Supp):34-40 (1988).*
DeLey, et al. “Neuroendocrine and epithelial antigens in SCLC,” Lung Cancer, 4:42-44 (1988).*
Udea et al., “Serological and Biochemical Analysis of four antigens associated with SCLC,” Lung Cancer, 4:96-98. (1988).*
Hirohashi et al., “145KDa cell membrane Ag on SCLCs as a common target for several MAb raised against SCLCs,” Lung Cancer, 4:103-104. (1988).*
Rosier et al., “Flow cytometry analysis of the reactivity on human blood leucocytes of a group of Mab reacting with SCLC and neural tissues,” Lung Cancer, 4:58-61. (1988).*
Roitt, Encyclopedia of Immunology, 1992, Academic Press, London, U.K., pp. 1444-1445.*
S. Pahlman et al., “Purification and Characterization of Human Neuron-Specific Enolase: Radioimmunoassay Development,” Tumour Biology, 5:127-139 (1984).*
A. Maier et al., “Expression of the Small Cell Carcinoma Antigens of Cluster-5 and Cluster 5-A in Primary Lung Tumours,” Br. J. Cancer, 59:692-695 (1989).*
R. L. Souhami et al., “The First International Workshop on Small Cell Lung Cancer Antigens,” Lung Cancer, 4:1-4 (1988).*
K. Patel et al., “Neural Cell Adhesion Molecule (NCAM) is the Antigen Recognized by Monoclonal Antibodies of Similar Specific in Small-Cell Lung Carcinoma and Neuroblastoma,” Int. J. Cancer, 44:573-578 (1989).*
K. Patel et al., “Monoclonal Antibody UJ13A Recognizes the Neural Cell Adhesion Molecule (NCAM),” Int. J. Cancer, 44:1062-1068 (1989).*
J. Finne et al., “An IgG Monoclonal Antibody to Group B Memingococci Cross-Reacts with Developmentally Reguated Polysialic Acid Units of Glycoproteins in Neural and Extraneural Tissues,” The Journal of Immunology, 0022-1767:4402-4407 (1987).*
J. Hayrinen et al., “Interaction of Meningococcal Group B Monoclonal Antibody and its Fab Fragment with &agr;2-8-Linked Sialic Acid Polymers: Requirement of a Long Oligosaccharide Segment fro Binding, ” Molecular Immunology, 26:523-529 (1989).*
P. T. Jones et al., “Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse,” Nature, 321:522-525 (1986).*
M. Verhoeyen et al., “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science, 239:1534-1536 (1988).*
M. Shulman et al., “A Better Cell Line for Making Hybridomas Secreting Specific Antibodies,” Science, 276:269-270 (1978).*
G. Kohler et al., “Continuous Cultures of Fused Cells Secreting Antibody of Predefined specificity,” Nature, 256:495-497 (1975).*
J. L. Cordell et al., “Immunoenzymatic Labeling of Monoclonal Antibodies Using Immune Complexes of Alkaline Phosphatase and Monoclonal Anti-alkaline Phosphatase (APAAP Complexes), ” The Journal of Histochemistry and Cytochemistry, 32:219-229 (1984).*
P. L. Ey et al., “Isolation of Pure IgG.sub.1, IgG.sub.2b Immunoglobulins From Mouse Serum Using Protein A-Sepharose,” Immunochemistry, 15:429-436 (1978).*
Kibbelaar, R. E., et al., “Expression of the Embryonal Neural Cell Adhesion Molecule N-Cam in Lung Carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer,”J. Pathol.159:23-28 (1989).
Watanabe, J. et al., “Monoclonal Antibody that Distinguishes Small-Cell Lung Cancer from Non-Small-Cell Lung Cancer,”Cancer Res.47:826 (1987).
Kitty Moolenaar, C., et al., “Expression of Neural Cell Adhesion Molecule-related Sialoglycoprotein in Small Cell Lung Cancer and Neuroblastoma Cell Lines H69 and CHP-212,”Cancer Res.50:1102-1106 (1990).
Fuchs, B. B., et al., “Biochemical and Immunochemical Analysis of Gangliosides of Human Small Cell Lung Carcinoma: Production of Monoclonal Antibodies against a Unique Marker of Small Cell Lung Carcinoma, Ganglioside Fuc GM1” Biotechnology and Applied Biochemistry10: 273-286 (1988).
Auerbach Bernhard
Bosslet Klaus
Peters Helmut
Dade Behring Marburg GmbH
Finnegan, Henderson Farabow, Garrett and Dunner L.L.P.
Ketter James
LandOfFree
Monoclonal antibodies against tumor-associated antigens, a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies against tumor-associated antigens, a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies against tumor-associated antigens, a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2857264